LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Long Term Debt

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Long Term Debt

LBRX · NASDAQ
CompanyLong Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
14.13M
N/AN/AN/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
0.00
N/AN/AN/A
53.60M
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
35.44M
-2.8%5.3%N/A
24.74M
N/AN/AN/A
0.00
N/AN/AN/A
46.38M
17.4%N/AN/A
7.81M
N/AN/AN/A
0.00
N/AN/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
0.00
N/AN/AN/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95